Angioimmunoblastic T-cell Lymphoma
Conditions
Interventions
Experimental group:Chidamide, Azacitidine, and Thalidomide
Sponsors
The First Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age > = 65 years, or length = 15 mm and short diameter > = 10 mm, and uptake of lesions on 18FDG-PET scan. 4. Eastern Cooperative Oncology Group (ECOG) performance status = 1.0×10^9/L, platelet count (PLT) > = 50×10^9/L, hemoglobin (HGB) >= 70g/L. Liver function: serum total bilirubin (TBIL) <=2× upper limit of normal value (ULN); alanine aminotransferase (ALT) and aspartate transferase (AST) <=3×ULN. Renal function: serum creatinine (Cr) <=2×ULN. 6. Voluntary participation, willing to provide the above treatment data, signed and dated informed consent.
Exclusion criteria
Exclusion criteria: 1.Allergic to the medication used. 2.With unstable or active cardiovascular diseases, had active infections that were not effectively controlled by the drug within one week before the first study medication, including HBV and HCV active infections. 3. Accompanied by severe hemophagocytic syndrome. 4. With other malignant tumors that still require treatment. 5. Serious mental or neurological disorders that affect informed consent and/or adverse reaction statements or observations. 6. Pregnant and lactating women, as well as reproductive age patients who are unwilling to take contraceptive measures. 7. Patients cannot be followed up. 8. Determined by researchers that the patients are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall reaction rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year progression-free survival rate;3-year overall survival rate;Safety; | — |
Countries
China
Contacts
Public ContactZhen Cai, Jingsong He
The First Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed